Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination With AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients With Advanced Cancer
Sponsor: Agenus Inc.
This PHASE1 trial investigates Advanced Cancer and is currently completed. Agenus Inc. leads this study, which shows 18 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
18 versions recorded-
Feb 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
May 2023 — May 2024 [monthly]
Recruiting PHASE1
▶ Show 13 earlier versions
-
Sep 2022 — May 2023 [monthly]
Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE1
-
Feb 2022 — Jun 2022 [monthly]
Recruiting PHASE1
-
Apr 2021 — Feb 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
May 2020 — Jul 2020 [monthly]
Recruiting PHASE1
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE1
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE1
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE1
-
Dec 2019 — Feb 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Nov 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Sep 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Agenus Inc.
For direct contact, visit the study record on ClinicalTrials.gov .